Trial to test new approach to improve large tumor treatment

Physician researcher first at UC to receive American Cancer Society career development grant

A new clinical trial at the University of Cincinnati Cancer Center will test the safety and effectiveness of a more targeted radiation dose for patients with large tumors. 

Andrew Frankart, MD, is leading the trial, supported by a five-year, $729,000 American Cancer Society (ACS)/American Society for Radiation Oncology (ASTRO) Clinician Scientist Development Grant. 

Trial details

The research focuses on a method of delivering radiation called lattice therapy, where certain parts of tumors are preferentially targeted with higher doses of radiation compared to other areas. 

“That allows you to achieve higher doses within a tumor, hopefully get better tumor control and also avoid some of the side effects that come with escalated doses of radiation to normal tissue,” said Frankart, a Cancer Center physician researcher and assistant professor of radiation oncology in UC’s College of Medicine. 

Frankart recently presented research at the ASTRO annual meeting that found complex lattice therapy plans can be developed quickly enough to be used clinically to treat tumors at various challenging sites in the body.

231117aFrankart021.CR2
Dr. Andrew Frankart, radiation oncology faculty member who just received an American Cancer Society grant, with radiation equipment at the Barrett Cancer Center.

The trial will test lattice therapy radiation that delivers a more targeted dose to cancer cells and aims to avoid side effects to healthy surrounding tissue. Photo/Andrew Higley/UC Marketing + Brand.

“We were able to demonstrate successfully that it is not something that takes a lot of extra time despite it being a much more complex planning approach,” he said. “We’ve gotten the information that we need, so we will be focusing more on the clinical outcomes now.” 

The grant will support the translation of Frankart’s findings into clinical practice through the trial, which is expected to enroll 37 adult patients and analyze the underlying biology of tumor and immune responses to lattice therapy radiation.  

“We’re focusing on patients who have large or bulky tumors. The approach is more based upon where it’s located and how large it is, and those are things that have previously prevented radiation from being as effective,” Frankart said. “Using this new approach to overcome some of those barriers hopefully means it can benefit more patients because we’re broadly including multiple disease sites.” 

Frankart has a clinical focus on pediatric cancer, seeing patients at the Cincinnati Children’s/University of Cincinnati Medical Center Proton Therapy Center. He said he hopes the findings from this trial for adult patients will also later translate to pediatric cancer.

Career development

Vinita Takiar, MD, PhD, Frankart’s mentor on the project, said the goal is for this research to lay the foundation for a career trajectory for Frankart focused on the use and study of lattice therapy more broadly. 

“We look forward to learning how to use it best and which patients will benefit from it the most,” said Takiar, a Cancer Center physician researcher, professor and vice chair of research in UC’s Department of Radiation Oncology. “We also hope to optimize the delivery so that it can be used more broadly in the community.” 

Frankart completed his undergraduate degree, medical school and residency all at UC, becoming a faculty member in August. The ACS/ASTRO grant is awarded to an early-career physician interested in having research be a significant part of their practice. 

231117aFrankart019.CR2
Dr. Andrew Frankart, radiation oncology faculty member who just received an American Cancer Society grant, with radiation equipment at the Barrett Cancer Center.

Frankart completed his undergraduate degree, medical school and residency at UC before joining the faculty earlier this year. Photo/Andrew Higley/UC Marketing + Brand.

“The grant is certainly a reflection of the excellent mentorship I’ve received through residency and the support of the department more broadly,” he said. “Since my time as an undergrad, I’ve always felt like UC is a special place to be part of within the medical community. Throughout the Cancer Center, at UC and Cincinnati Children’s, you can tell that everyone cares about what they’re doing and they care about the patients as individuals. They also care about each other within the medical team, and I think that leads to outstanding care for our patients.” 

Frankart is the first UC researcher to receive the grant, and only one researcher nationwide is awarded this grant every year. Mentor Takiar said Frankart embodies many characteristics essential to being a successful physician researcher, including “attention to detail, learning from every opportunity and putting in the hard work.” 

“Career development awards are essential in allowing sufficient research time for early-career investigators to really focus on the research project,” Takiar said. “Dedicated time for both career and project development sets the foundation for physician-scientists for the early years as well as those to come.” 

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.

Featured photo at top of Frankart in a radiation treatment room. Photo/Andrew Higley/UC Marketing + Brand.

Related Stories

8397 Results
1

President picks exceptional talent

April 28, 2021

The University of Cincinnati 2021 Presidential Leadership Medal of Excellence Awards honor six undergraduate scholars for scholarship, leadership, character, service and the ideals of the university. Awardees are spotlighted for exceptional academics, creativity, community service and innovation.

2

Grad students earn president's highest honor

April 28, 2021

The University of Cincinnati 2021 Presidential Medal of Graduate Student Excellence Awards honor three graduate scholars for scholarship, leadership, character, service and the ideals of the university. Awardees are spotlighted for exceptional academics, creativity, community service and innovation.

3

Local 12: 180 UC med students receive white coats, students embark on journey during pandemic

August 9, 2021

The University of Cincinnati College of Medicine welcomed 180 newly admitted first-year students during the college’s 26th annual White Coat Ceremony. The ceremony was held Friday at 10 a.m. at Cincinnati Music Hall, 1241 Elm Street. Each member of the class of 2025 were presented with a white lab coat, symbolizing entry into the medical profession. Local 12 covered the event.

4

Finding community and building a future

July 9, 2021

As a University of Cincinnati College of Medicine student, Sarah Appeadu, MD, ’21, remembers journaling on the “3 Cs” that got her through medical school: Community, community, community. Now, when she lists the people who supported her through four years of training—the last year in a global pandemic—it keeps growing: her family, her church, her classmates, and the college’s Office of Student Affairs and Office of Diversity, Equity and Inclusion. “I look back and it was such a crucial time to really be nurtured in that way,” she says. “I’m so thankful that I had those people. It shows being around the right people really mattered. That’s my same hope for residency even.”

8

UC Receives $1.9 Million to Study Pain

February 15, 2016

Jun-Ming Zhang, MD, of the UC College of Medicine, is the principal investigator of a $1.95 million grant to study the interacting roles of the sympathetic and sensory nervous and immune systems in back and neuropathic pain models.

9

MD Magazine: Generic Drug Equally Effective in Epilespy

February 22, 2016

Michael Privitera, MD, a professor of neurology at UC's College of Medicine and director of the Epilepsy Center at the UC Neuroscience Institute, is featured in this story about research he led that examined the efficacy of generic drug substitution for epilepsy.